Dernières nouvelles pour Amarin Corp (NASDAQ:AMRN) Stock

Amarin Corp

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Amarin Corporation plc - American Depositary Shares

Amarin Corp PLC

Amarin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) shares are trading higher Tuesday after the company announced a long-term exclusive license and supply agreement with Recordati S.p.A. to commercialize its cardiovascular drug VAZKEPA (icosapent ethyl) <a href="https://www.benzinga.com/pressreleases/25/06/g46070277/amarin-announces-exclusive-license-and-supply-agreement-with-recordati-to-commercialize-vazkepa-ic">across 59 countries in Europe.</a>
What To Know: Under the terms of the deal, Amarin will receive $25 million in upfront cash and up to $150 million in additional milestone payments, tied to commercial net sales targets. Recordati will handle all commercialization activities for VAZKEPA in Europe.
The agreement allows Amarin to streamline its operations, particularly in Europe, which is expected to result in $70 million in cost savings over the next year. These reductions are part of a broader global restructuring effort aimed at accelerating the company's path to positive cash flow.
Amarin's CEO Aaron Berg said the partnership puts the company in a stronger strategic and financial position, citing nearly $300 million in cash, no debt and new revenue streams.
The company also reiterated its plans to focus on revenue generation in the U.S. and from global partnerships in Canada, China, the Middle East and Asia-Pacific regions, where commercialization efforts are already underway. The licensing deal with Recordati signals a shift toward a leaner, partnership-based international strategy.
AMRN Price Action: Amarin shares were up 33% at $16.76 at the time of writing, according to<a href="https://www.benzinga.com/pressreleases/25/06/g46070277/amarin-announces-exclusive-license-and-supply-agreement-with-recordati-to-commercialize-vazkepa-ic"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46067898/trumps-crypto-ventures-have-been-lucrative-but-adam-schiff-says-he-is-bringing-in-a-law-to-end-corruption-in-plain-sight">Trump&#8217;s Crypto Ventures Have Been &#8216;Lucrative,&#8217; But Adam Schiff Says He Is Bringing In A Law To End &#8216;Corruption In Plain Sight&#8217;</a></li>
</ul>
Image Via Shutterstock.

News

Movers

AMRN

Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA

Amarin Corporation Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) on Tuesday entered into an exclusive<a href="https://www.benzinga.com/pressreleases/25/06/g46070277/amarin-announces-exclusive-license-and-supply-agreement-with-recordati-to-commercialize-vazkepa-ic"> long-term license and supply agreement</a> with Recordati S.p.A., Italy, to commercialize Vazkepa (icosapent ethyl) in 59 countries, with a focus on Europe.
Vazkepa (Vascepa in the United States) is indicated to reduce the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">risk of cardiovascular events</a>. Amarin will streamline its global operations, further strengthening its financial position. Recordati will be responsible for commercializing Vazkepa in Europe.
Amarin will receive upfront cash of $25 million and milestone payments totaling up to $150 million contingent upon Recordati achieving predefined annual commercial net sales levels.
Also Read: <a href="https://www.benzinga.com/m-a/25/06/45907865/biontech-mrna-cancer-portfolio-curevac-all-stock-deal" target="_blank" rel="noreferrer noopener">BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal</a>
Amarin will also receive supply-based revenues, including royalties for the supply of the product under the terms of the agreement.
&#8220;This long-term partnership with Recordati for Vazkepa in Europe, where we have patent protection up to 2039, combined with the company&#8217;s financial strengths, nearly $300 million in cash, no debt, an estimated $70 million in cost savings over the next 12 months and continued cost efficient revenue generation from multiple revenue streams, accelerates the path to positive cash flow and strengthens our strategic position for the future,&#8221; said Aaron Berg, President &amp; CEO of Amarin.
Amarin will immediately initiate a global restructuring. Most of the estimated cost savings will come from reduced commercialization expenses in the company&#8217;s European operations. Streamlining global operations will drive an estimated $70 million in cost savings over the next 12 months.
Amarin will continue maximizing its U.S. business as a mature, profitable enterprise with meaningful cash flows. The company has multiple levers to continue to drive Vascepa revenue and cash flow generation.
Amarin will continue to generate revenue through its partnerships in key international markets.
Amarin reported a first-quarter 2025 adjusted loss of 2 cents per share, beating the consensus of a loss of 57 cents. Sales reached $42.02 million, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $50.75 million</a>.
The company said that while its direct commercialization efforts remain in various early stages across the 10 markets where Vazkepa is currently launched in Europe, aggregate in-market demand grew 16% sequentially quarter over quarter, <a href="https://www.benzinga.com/pressreleases/25/05/g45248074/amarin-reports-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">evidence of increasing momentum</a>.
Price Action: AMRN stock is trading higher by 34.5% at $16.95 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/46070241/fda-approves-astrazeneca-and-daiichi-sankyos-datroway-for-type-of-lung-cancer" target="_blank" rel="noreferrer noopener">FDA Approves AstraZeneca And Daiichi Sankyo&#8217;s Datroway For EGFR-Mutated Lung Cancer</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

General

Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges

<h3>Gainers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock increased by 128.3% to $21.78 during Tuesday's regular session. The market value of their outstanding shares is at $118.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 106.64% to $0.7. The company's market cap stands at $10.3 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares rose 71.71% to $9.41. The market value of their outstanding shares is at $15.7 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock increased by 32.85% to $16.74. The market value of their outstanding shares is at $260.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares increased by 29.29% to $0.71. The company's market cap stands at $10.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares rose 27.51% to $25.5. The company's market cap stands at $520.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 37.9% to $1.0 during Tuesday's regular session. The market value of their outstanding shares is at $19.4 million. </li>
<li>Ernexa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock decreased by 19.17% to $1.94. The company's market cap stands at $17.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 18.49% to $1.34. The market value of their outstanding shares is at $5.3 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares fell 12.09% to $3.94. The market value of their outstanding shares is at $85.2 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock fell 11.72% to $0.44. The company's market cap stands at $8.0 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares fell 11.6% to $0.23. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ERNA

EYEN

INDP

LIMN

NKTR

NTHI

ONMD

SNGX

TRIB

12 Health Care Stocks Moving In Tuesday's Intraday Session

INM: 102% &#x7C; <a href="https://www.benzinga.com//node/46070476">InMed shares are trading higher after the company announced preclinical data showing INM-901 reduced neuroinflammation markers in an ex vivo Alzheimer's disease study.</a>
&nbsp;
NA: 108% &#x7C; <a href="https://www.benzinga.com//node/46070530">Nano Labs shares are trading higher after the company announced a $500 million convertible notes private placement for its BNB treasury strategy.</a>
&nbsp;
AMRN: 7% &#x7C; <a href="https://www.benzinga.com//node/46070542">Amarin shares are trading higher after the company announced an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in Europe.</a>

Trading Ideas

Market-Moving News for June 24th

WIIM

Amarin shares are trading higher after the company announced an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in Europe.

Amarin Enters License And Supply Agreement With Recordati To Commercialize VAZKEPA In Europe; Amarin Will Receive $25M Upfront Payment And Milestones Totaling Up To $150M

Amarin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced that the Company has entered into an exclusive long-term license and supply agreement (the "Agreement") with Recordati S.p.A. ("Recordati") to commercialize VAZKEPA&#xAE; (icosapent ethyl) across 59 countries, focused in Europe. This Agreement capitalizes on the early-stage success of VAZKEPA in Europe by partnering with Recordati to accelerate the depth and reach of the product for patients at-risk of a cardiovascular event. As a result of the Agreement, Amarin will streamline its global operations, which further strengthens the Company's financial position.
Under the terms of the Agreement:
<ul>
<li>Recordati will be responsible for commercialization of VAZKEPA in Europe.</li>
<li>Amarin will receive:
<ul>
<li>Upfront cash of $25 million and milestone payments totalling up to $150 million contingent upon Recordati achieving predefined annual commercial net sales levels;</li>
<li>Supply-based revenues, including royalties for the supply of the product under the terms of the agreement &nbsp;</li>
</ul>
</li>
</ul>

Amarin Strikes $175M Deal With Recordati to Expand Heart Drug VAZKEPA Across 59 European Countries

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.57) by 96.49 percent. This is a 100 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $42.02 million which missed the analyst consensus estimate of $50.75 million by 17.20 percent. This is a 25.66 percent decrease over sales of $56.52 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Amarin Corp Q1 Adj. EPS $(0.02) Beats $(0.57) Estimate, Sales $42.02M Miss $50.75M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Amarin Corp to report an earnings per share (EPS) of $-0.02.
Investors in Amarin Corp are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 2.47% increase in the share price on the subsequent day.
Here's a look at Amarin Corp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.03</td>
<td>-0.05</td>
<td>-0.04</td>
<td>-0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>-0.05</td>
<td>0.01</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-4.0%</td>
<td>-9.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746540141_0.png" alt="eps graph" />
<h3>Performance of Amarin Corp Shares</h3>
Shares of Amarin Corp were trading at $10.6 as of May 05. Over the last 52-week period, shares are down 39.27%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AMRN/earnings">To track all earnings releases for Amarin Corp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Amarin Corp's Earnings Expectations

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.8% to $0.42 during Friday's pre-market session. The company's market cap stands at $16.7 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 16.81% to $2.64. The market value of their outstanding shares is at $154.6 million. The company's, Q1 earnings came out today. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares rose 16.15% to $7.19. The market value of their outstanding shares is at $113.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock moved upwards by 15.94% to $1.6. The company's market cap stands at $22.9 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares rose 12.93% to $1.22. The market value of their outstanding shares is at $41.5 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 12.76% to $2.12. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock fell 18.8% to $0.82 during Friday's pre-market session. The company's market cap stands at $51.3 million. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) stock decreased by 18.65% to $4.45. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 17.45% to $0.22. The company's market cap stands at $10.0 million. </li>
<li>Tvardi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) shares fell 17.1% to $21.1. The company's market cap stands at $197.4 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock fell 15.76% to $9.25. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined by 11.97% to $2.06. The market value of their outstanding shares is at $103.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

AMWL

ARDX

ATPC

CAMP

CTSO

HCTI

MODV

PLRZ

RMTI

TVRD

12 Health Care Stocks Moving In Friday's Pre-Market Session

-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing --
-- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA –
DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications.
On April 29, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of April 28, 2025 the Company's common stock had maintained an average closing share price of at least $1.00 over the last 10 consecutive business days ending on that date. Accordingly, the Company's shares are no longer considered to be below the minimum bid price requirement of Rule 5550(a)(2) and, as a result, the Company has regained compliance with the Nasdaq continued listing standards. Nasdaq now considers this matter closed.
Amarin is now in full compliance with all Nasdaq listing requirements and will continue to be listed and traded on Nasdaq.

Amarin Regains Compliance With Nasdaq Minimum Bid Price Requirement; Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing

As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Lexicon Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>)</h3>
<ul>
<li>On March 28, Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture, and commercialize LX9851 in all indications. The company's stock jumped around 95% over the past month and has a 52-week high of $2.45.</li>
<li>RSI Value: 73.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LXRX Price Action: Shares of Lexicon Pharmaceuticals gained 4.7% to close at $0.70 on Thursday.</li>
<li>Edge Stock Ratings: 5.71 Momentum score with Value at 55.06. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/lxrx"><img loading="lazy" decoding="async" width="472" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168.png" alt="" class="wp-image-888292" style="width:303px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168.png 472w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168-300x116.png 300w" sizes="(max-width: 472px) 100vw, 472px" /></a></figure>
<h3 class="wp-block-heading">Amarin Corporation PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>)</h3>
<ul>
<li>On March 12, Amarin announced its intent to effect a 1-for-20 ADS ratio change. The company also reported fourth-quarter financial results. &#8220;Since taking on the role of CEO of Amarin last year, I have worked with our leadership team and the Board of Directors to identify opportunities to leverage our unique assets, skills and resources to drive value,&#8221; said Aaron Berg, President &amp; CEO, Amarin. &#8220;In 2024, while still progressing with the early launch in markets outside the U.S. and despite a dynamic generic market in the U.S., we generated more than $200 million in revenue and ended the year with nearly $300 million in cash and no debt &#8212; all measures exemplifying the strength and resilience of our franchise and the impact of our disciplined approach to capital deployment.&#8221; The company's stock gained around 24% over the past five days and<a href="https://www.benzinga.com/quote/AMRN"> has a 52-week high</a> of $20.60.</li>
<li>RSI Value: 73.5</li>
<li>AMRN Price Action: Shares of Amarin rose 7.9% to close at $11.18 on Thursday.</li>
</ul>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44977071/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 7% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

LXRX

Top 2 Health Care Stocks That May Crash This Month

Goldman Sachs analyst Paul Choi maintains Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) with a Sell and lowers the price target from $20 to $7.

Price Target

Analyst Ratings

Goldman Sachs Maintains Sell on Amarin Corp, Lowers Price Target to $7

U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Monday.
Shares of Hyatt Hotels Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) fell sharply during <a href="https://www.benzinga.com/quote/H/analyst-ratings">Monday's session</a>.
Goldman Sachs analyst Lizzie Dove downgraded Hyatt Hotels from Neutral to Sell and lowered the price target from $150 to $110.
Hyatt Hotels shares fell 2.2% to $110.13 on Monday.
Here are some other big stocks recording losses in today's session.
<ul>
<li>Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares dipped 9.9% to $5.84.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) tumbled 9.9% to $119.00.</li>
<li>Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) shares fell 9.3% to $8.44.</li>
<li>Clear Channel Outdoor Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) shares declined 8.2% to $0.9453.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) fell 5.9% to $17.75. Truist Securities analyst Michael Swartz maintained MarineMax with a Buy and lowered the price target from $38 to $26.</li>
<li>Wheels Up Experience Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) dipped 5.7% to $0.8010.</li>
<li>ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) fell 5.6% to $0.8969. ECARX Holdings will report its financial results for the first quarter, before the opening bell on Wednesday, April 30.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) declined 5.5% to $3.2200.</li>
<li>SBC Medical Group Holdings Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NASDAQ">SBC</a>) fell 4.8% to $4.00. SBC Medical Group completed its purchase of 5 BTC as of April 14.</li>
<li>THOR Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) fell 2.5% to $67.25. Truist Securities analyst Michael Swartz maintained Thor Industries with a Hold and lowered the price target from $90 to $72.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44759831/top-3-industrials-stocks-that-may-explode-in-april">Top 3 Industrials Stocks That May Explode In April</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

ALMS

NUTX

SHLS

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

U.S. stocks were lower, with the Dow Jones index dipping over 250 points on Friday.
Shares of Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) rose sharply during Thursday's session following better-than-<a href="https://www.benzinga.com/news/earnings/25/04/44761872/fastenal-beats-revenue-estimates-in-q1-but-margins-narrow-as-costs-rise">expected first-quarter sales.</a>
Fastenal on Friday reported first-quarter 2025 revenue of $1.959 billion, a 3.4% year-over-year increase and slightly above the $1.95 billion consensus estimate. Adjusting for one less selling day and the absence of Good Friday in March, net daily sales grew 5.0%.
Fastenal shares jumped 3.3% to $78.31 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>CeriBell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares jumped 30.3% to $14.52.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) gained 28% to $5.77.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) rose 19.3% to $30.72. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 16.2% to $28.26.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) rose 15.2% to $2.8300.</li>
<li>Schrödinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) gained 13.6% to $21.84.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 13.55% to $32.07.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) rose 12.6% to $11.84. Baird analyst Joe Vruwink maintained Certara with a Neutral and raised the price target from $9 to $13.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) gained 12% to $8.18.</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) gained 10.6% to $230.00.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) gained 10.6% to $28.11.</li>
<li>AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) rose 8.5% to $42.15.</li>
<li>Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) jumped 7.6% to $9.72.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44759875/mckesson-to-rally-more-than-11-here-are-10-top-analyst-forecasts-for-friday">McKesson To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday</a> </li>
</ul>
Photo via Shutterstock

ABSI

CBLL

CERT

FAST

NMAX

RXRX

SDGR

ZLAB

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic&nbsp;acid (EPA) on lipoprotein(a) [Lp(a)]-enriched plasma and the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist in combination with EPA on the expression of proteins in endothelial cells.

Amarin Highlights Recent Data Presented At ACC.25 Evaluating Mechanistic Effects Of Eicosapentaenoic Acid In Lp(a)-Enriched Plasma And In Combination With GLP-1 Agonist

Amarin Corporation shares are trading lower after the company announced its intent to effect a 1-for-20 ADS ratio change. The company reported Q4 financial results.

Press Releases

Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist

Management

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Amarin Reports First Quarter 2025 Financial Results

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

Comments

Amarin Corp

Actualités

Dernières nouvelles pour Amarin Corp (NASDAQ:AMRN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL